KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Deferred Taxes (2021 - 2025)

Castle Biosciences' Deferred Taxes history spans 5 years, with the latest figure at -$907000.0 for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 60.68% year-over-year to -$907000.0; the TTM value through Dec 2025 reached -$6.2 million, down 544.54%, while the annual FY2025 figure was -$6.2 million, 544.54% down from the prior year.
  • Deferred Taxes for Q4 2025 was -$907000.0 at Castle Biosciences, down from $116000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $5.2 million in Q3 2024 and bottomed at -$8.7 million in Q4 2021.
  • The 5-year median for Deferred Taxes is -$770000.0 (2025), against an average of -$1.2 million.
  • The largest annual shift saw Deferred Taxes skyrocketed 99.57% in 2022 before it tumbled 877.54% in 2024.
  • A 5-year view of Deferred Taxes shows it stood at -$8.7 million in 2021, then surged by 99.57% to -$38000.0 in 2022, then plummeted by 521.05% to -$236000.0 in 2023, then crashed by 877.54% to -$2.3 million in 2024, then skyrocketed by 60.68% to -$907000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Deferred Taxes are -$907000.0 (Q4 2025), $116000.0 (Q3 2025), and -$4.7 million (Q2 2025).